RESEARCHER PROFILE
Professor Stuart Brierley (Filmed February 2024)
Director of the Visceral Pain Research Group,
Director of the Hopwood Centre for Neurobiology &
Theme co-Leader of Lifelong Health
South Australian Health and Medical Research Institute (SAHMRI)
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
He has developed a strong track record in coordinating and working in multi-faceted research programs for high impact publications in journals. His work has attracted four NHMRC Fellowships including other NHMRC and NIH grants.
The global pandemic has shed light on the severity of the Opioid Crisis, highlighting the urgent need for effective pain treatments. During his 24 years as a researcher, Professor Brierley has made significant strides in understanding how pain arises from the gastrointestinal tract or the gut.
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
His research comprises discovery and translational science investigating the nerve pathways innervating visceral organs to determine the causes of, and treatments for, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), bladder pain syndrome, and endometriosis.
Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) disorders are highly prevalent, affecting up to 15% of the Western population.
Despite being a major global clinical issue, pain, especially from the gastrointestinal tract, lacks effective treatments, and the research focuses on understanding and treating pain in gastrointestinal diseases in order to develop targeted treatments. Individual gut cells communicate with the brain to signal pain and trigger symptoms that include depression and anxiety.
Professor Brierley is collaborating with researchers in Australia and internationally including Nobel Prize winner Nobel Prize Laureate Professor David Julius, Professor Holly Ingraham and Dr Jim Bayrer at the University of California San Francisco, all with the goal of helping people.
His research interests extends into other common causes for visceral pain including interstitial cystitis/painful bladder syndrome and endometriosis and how ‘cross-organ sensitisation’ can potentially explain co-morbidities in these patients.
Pain is a global issue, and Professor Brierley’s work aims to understand its causes in order to develop targeted treatments, while also balancing a busy family life and various interests.
You Might also like
-
Elite athlete physical and mental health impact performance
Understanding the interaction between genes and lifestyle factors in response to stress can lead to potential therapeutic interventions for stress-related disorders. This research is crucial for promoting health and well-being.
Professor Mehta has recently commenced research into elite athlete physical and mental health impact performance, with research at the intersection of statistics, genomics, and mental health. This research is ahead of, and in anticipation of, the Summer Olympics in Brisbane in 2032.
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
-
Lymphoma, Myeloma and Genomics
Professor Dipti Talaulikar is a clinical and laboratory haematologist with expertise in genomics, working at Canberra Health Services, and Professor at ANU. She has a clinical and research interest in lymphoma, myeloma and genomics, and has authored close to 100 peer reviewed papers, including several clinical guidelines that have had a significant impact on clinical practice.